Home Cart Sign in  
Chemical Structure| 509088-69-1 Chemical Structure| 509088-69-1

Structure of Mocravimod HCl
CAS No.: 509088-69-1

Chemical Structure| 509088-69-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KRP-203 is a selective Sphingosine-1-phosphate receptor agonist that has been shown to reduce peripheral lymphocyte infiltration and to prolong survival in rat transplant models.

Synonyms: Krp-203; Mocravimod hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mocravimod HCl

CAS No. :509088-69-1
Formula : C24H27Cl2NO3S
M.W : 480.45
SMILES Code : OCC(CCC1=CC=C(SC2=CC=CC(OCC3=CC=CC=C3)=C2)C=C1Cl)(N)CO.[H]Cl
Synonyms :
Krp-203; Mocravimod hydrochloride
MDL No. :MFCD09952233

Safety of Mocravimod HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Mocravimod HCl

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01830010 Hematological Malignancies Phase 1 Completed - France ... More >> Novartis Investigative Site Paris, France, 75010 Germany Novartis Investigative Site Regensburg, Bavaria, Germany, 93053 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Hamburg, Germany, 20246 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Koeln, Germany, 50937 Switzerland Novartis Investigative Site Basel, Switzerland, 4031 Novartis Investigative Site Zürich, Switzerland, 8091 Less <<
NCT01375179 Ulcerative Colitis Phase 2 Terminated - Belgium ... More >> Novartis Investigative Site Gent, Belgium, 9000 Novartis Investigative Site Leuven, Belgium, 3000 Germany Novartis Investigative Site Frankfurt am Main, Germany, 60318 Novartis Investigative Site Hamburg, Germany, 20148 Novartis Investigative Site Köln, Germany, 51103 Hungary Novartis Investigative Site Budapest, Hungary, 1083 Novartis Investigative Site Debrecen, Hungary, 4032 Sweden Novartis Investigative Site Stockholm, Sweden, 116 91 Novartis Investigative Site Stockholm, Sweden, SE-141 86 Novartis Investigative Site Uppsala, Sweden, 751 85 Switzerland Novartis Investigative Site Bern, Switzerland, 3010 Novartis Investigative Site Zurich, Switzerland, 8091 United Kingdom Novartis Investigative Site Oxford, Oxfordshire, United Kingdom, OX3 9DU Novartis Investigative Site Nottingham, United Kingdom, NG7 2UH Less <<
NCT01294774 Subacute Cutaneous Lupus Eryth... More >>ematosus Less << Phase 2 Completed - Germany ... More >> Novartis Investigative Site Bochum, Germany, 44791 Novartis Investigative Site Bonn, Germany, 53105 Novartis Investigative Site Frankfurt am Main, Germany, 60596 Novartis Investigative Site Tuebingen, Germany, 72076 Greece Novartis Investigative Site Athens, GR, Greece, 161 21 Novartis Investigative Site Thessaloniki, GR, Greece, 546 29 Italy Novartis Investigative Site Genova, GE, Italy, 16132 Novartis Investigative Site Siena, SI, Italy, 53100 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.08mL

0.42mL

0.21mL

10.41mL

2.08mL

1.04mL

20.81mL

4.16mL

2.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories